Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
Clin Cancer Res
    May 2025
  1. RODRIGUEZ-MORENO JF, de Velasco G, Alvarez-Fernandez C, Collado R, et al
    Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
    Clin Cancer Res. 2025;31:1644-1656.
    >> Share

    February 2025
  2. GARCIA-DEL-MURO X, P Valderrama B, Medina-Colmenero A, Etxaniz O, et al
    Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
    Clin Cancer Res. 2025;31:659-666.
    >> Share

    January 2025
  3. QIE Y, Huang S, Shen C, Wu Z, et al
    Phase 2 pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder cancer.
    Clin Cancer Res. 2025 Jan 7. doi: 10.1158/1078-0432.CCR-24-3321.
    >> Share

    December 2024
  4. COLBERT L, Jia Y, Sharma A, Hu J, et al
    FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
    Clin Cancer Res. 2024 Dec 20. doi: 10.1158/1078-0432.CCR-24-2812.
    >> Share

  5. FLECHON A, Morales-Barrera R, Powles T, Alva A, et al
    Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:5353-5364.
    >> Share

    November 2024
  6. BRAVE MH, Maguire WF, Weinstock C, Zhang H, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:4815-4821.
    >> Share

    September 2024
  7. EISNER JR, de Jong FC, Shibata Y, Mayhew GM, et al
    Characterization of Fibroblast Growth Factor Receptor Alterations and Activation in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.
    Clin Cancer Res. 2024 Sep 26. doi: 10.1158/1078-0432.CCR-24-2015.
    >> Share

  8. ZANG J, Shahatiaili A, Cai MC, Jin D, et al
    Genomic profiling and immune phenotyping of neuroendocrine bladder cancer.
    Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1277.
    >> Share

    July 2024
  9. CHELUSHKIN MA, van Dorp J, van Wilpe S, Seignette IM, et al
    Platinum-based chemotherapy induces opposing effects on immunotherapy response-related spatial and stromal biomarkers in the bladder cancer microenvironment.
    Clin Cancer Res. 2024 Jul 24. doi: 10.1158/1078-0432.CCR-24-0724.
    >> Share

    May 2024
  10. MAGUIRE WF, Lee D, Weinstock C, Gao X, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:2011-2016.
    >> Share

  11. BALASOORIYA ER, Wu Q, Ellis H, Zhen Y, et al
    The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Clin Cancer Res. 2024;30:2181-2192.
    >> Share

    January 2024
  12. PETRYLAK DP, Eigl BJ, George S, Heath EI, et al
    Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:63-73.
    >> Share

    December 2023
  13. LINDSKROG SV, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, et al
    Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Clin Cancer Res. 2023;29:4797-4807.
    >> Share

    November 2023
  14. LERNER SP, McConkey DJ, Tangen CM, Meeks JJ, et al
    Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
    >> Share

  15. GUERCIO BJ, Sarfaty M, Teo MY, Ratna N, et al
    Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Clin Cancer Res. 2023;29:4586-4595.
    >> Share

  16. DRAKAKI A, Powles T, Bamias A, Martin-Liberal J, et al
    Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
    Clin Cancer Res. 2023;29:4373-4384.
    >> Share

    October 2023
  17. KAMRAN SC, Zhou Y, Otani K, Drumm M, et al
    Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0792.
    >> Share

  18. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    >> Share

  19. LI R, Sexton WJ, Dhillon J, Berglund A, et al
    A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
    Clin Cancer Res. 2023;29:3875-3881.
    >> Share

    September 2023
  20. SALARI K, Sundi D, Lee JJ, Wu S, et al
    Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
    Clin Cancer Res. 2023;29:3668-3680.
    >> Share

  21. JIANG D, Lan X, Cai W
    PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
    Clin Cancer Res. 2023;29:3259-3261.
    >> Share

  22. DUAN X, Xia L, Zhang Z, Ren Y, et al
    First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2023;29:3395-3407.
    >> Share

    August 2023
  23. ZHANG R, Zang J, Jin D, Xie F, et al
    Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0513. doi: 10.1158/1078-0432.CCR-23-0513.
    >> Share

    June 2023
  24. JANG HJ, Hostetter G, Macfarlane AW, Madaj Z, et al
    A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2023;29:2052-2065.
    >> Share

    April 2023
  25. AGGEN DH, Chu CE, Rosenberg JE
    Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1377-1380.
    >> Share

  26. KLUMPER N, Ralser DJ, Ellinger J, Roghmann F, et al
    Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1496-1505.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016